Abstracts tagged "Adalimumab"

Abstract Number: 772 • 2012 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy Compared with Adalimumab Monotherapy in Patients with Rheumatoid Arthritis: Results of a 24-Week Study
Arthur Kavanaugh¹, Paul Emery², Ronald F. van Vollenhoven³, Ara H. Dikranian⁴, Rieke Alten⁵, Micki Klearman⁶, David Musselman⁷, Sunil Agarwal⁷, Jennifer Green⁸ and Cem Gabay⁹, ¹UCSD School of Medicine, La Jolla, CA, ²Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ³Karolinska Institute, Stockholm, Sweden, ⁴San Diego Arthritis Medical Clinic, San Diego, CA, ⁵Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ⁶Roche, South San Francisco, CA, ⁷Genentech Inc, South San Francisco, CA, ⁸Roche, Welwyn Garden City, United Kingdom, ⁹Rheumatology, Geneva University Hospitals, Geneva, Switzerland
Background/Purpose: Approximately one-third of RA pts treated with biologics receive them as monotherapy (ie, without other DMARDs).1-3 Although tocilizumab (TCZ), an IL-6 receptor inhibitor, has…
Abstract Number: 2160 • 2012 ACR/ARHP Annual Meeting
Fcγ Receptor IIIb Polymorphism Is Associated with Injection Reaction to Adalimumab in Patients with Rheumatoid Arthritis
Masako Tsukamoto¹, Yosuke Hashimoto¹, Tatsuhiro Ohshige¹, Keiko Yoshimoto², Yuko Kaneko³, Hideto Kameda² and Tsutomu Takeuchi⁴, ¹Division of Rheumatology, Department of Internal medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Dept of Internal Medicine, Keio Univ School of Medicine, Shinjuku-ku, Japan, ⁴Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Biological agents targeting a specific molecule provide an effective means for therapeutic management of rheumatoid arthritis (RA), but infusion/injection reaction is a major adverse…
Abstract Number: 580 • 2012 ACR/ARHP Annual Meeting
Changes in Sclerostin, Dickkopf-1 and Serum Markers of Inflammation, Cartilage and Bone Turnover in Patients with Axial Spondyloarthritis Treated with Adalimumab
Susanne Juhl Pedersen¹, Inge Juul Sørensen², Julia S. Johansen³, Patrick Garnero⁴, Anne Gitte Loft⁵, Jens Skoedt⁶, Gorm Thamsborg⁷, Karsten Asmussen⁸, Elka Kluger⁹, Jesper Nørregaard¹⁰, Torben Grube Christensen¹¹ and Mikkel Østergaard¹², ¹Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ²Department of Rheumatology, Hvidovre Hospital, Copenhagen, Denmark, ³Department of Internal Medicine and Oncology, Herlev Hospital, Herlev, Denmark, ⁴INSERM, UMR 1033, Lyon and Cisbio Bioassays, Bagnols/Cèze, France, ⁵Department of Rheumatology, Sygehus Lillebaelt, Vejle, Denmark, ⁶Department of Rheumatology, Gentofte Hospital, Copenhagen, Denmark, ⁷Dep. of Rheumatology, Glostrup Hospital, Copenhagen, Denmark, ⁸Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ⁹King Christian 10th Rheumatism Hospital at Gråsten, Graasten, Denmark, ¹⁰Dep of Rheumatology, Hørsholm Hospital, Hørsholm, Denmark, ¹¹Department of Rheumatology, Slagelse Hospital, Slagelse, Denmark, ¹²Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: Few studies have investigated changes in plasma sclerostin and Dickkopf1 (DKK-1) in relation to other biomarkers of inflammation, cartilage and bone turnover during treatment…
Abstract Number: 2010 • 2012 ACR/ARHP Annual Meeting
Administration of Routine Preventative Vaccinations in Children with Juvenile Idiopathic Arthritis Receiving Adalimumab
Neelufar Mozaffarian¹ and Vipin Arora², ¹Abbott, Abbott Park, IL, ²Health Outcomes Research, Abbott, Abbott Park, IL
Background/Purpose: Adalimumab, a fully human monoclonal antibody to tumor necrosis factor-alpha (TNF) has been shown to be safe and effective in juvenile idiopathic arthritis (JIA),…
Abstract Number: 568 • 2012 ACR/ARHP Annual Meeting
14-3-3 Eta Is a Modifiable Serum Biomarker That Marks Adalimumab Response in Psoriatic Arthritis
Anthony Marotta¹, A. W van Kuijk², Walter P. Maksymowych³ and Paul Peter Tak⁴, ¹Augurex Life Sciences Corp, North Vancouver, BC, Canada, ²Clinical Immunology / Rheumatology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ³Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁴Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: 14-3-3 eta is a synovial-derived biomarker whose serum expression is independently associated with joint damage in RA and PsA. We previously reported that 14-3-3…
Abstract Number: 1973 • 2012 ACR/ARHP Annual Meeting
Effect of Adalimumab On the Serum Level of Undercarboxylated Osteocalcin (ucOC), Bone Biochemical Markers and Bone Mineral Density
Yoshitada Sakai¹, Akira Hashiramoto², Takaichi Okano², Yoshiko Kawasaki³, Nao Shibanuma⁴ and Masahiro Kurosaka⁵, ¹The Center of Rheumatic Diseases/ Division of Rehabilitation Medicine, Kobe University Hospital, Kobe, Japan, ²The Center for Rheumatic Diseases,, Kobe University Hospital, Kobe, Japan, ³The Center of Rheumatic Diseases, Kobe University Hospital, Kobe, Japan, ⁴The Center for Rheumatic Diseases, Kobe University Hospital / Departmant of Orthopaedic Surgery, Kobe Kaisei Hospital, Kobe, Japan, ⁵Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: The osteoporotic fracture in patients with rheumatiod arthritis (RA) is caused by systemic osteoporosis as well as periarticular osteoporosis, On the other hand, the…
Abstract Number: 484 • 2012 ACR/ARHP Annual Meeting
Comparison of Rheumatoid Arthritis-Related Health Care Resource Use and Comorbidities Among Patients with Rheumatoid Arthritis Treated with Adalimumab Vs. Etanercept
Jipan Xie¹, Arijit Ganguli², Hongbo Yang¹, Kejal Parikh¹, Eric Q. Wu¹ and Mary Cifaldi³, ¹Analysis Group Inc., Boston, MA, ²AbbVie, North Chicago, IL, ³Abbott Laboratories, Abbott Park, IL
Background/Purpose: Adalimumab (ADA) and etanercept (ETN) are two commonly used tumor necrosis factor (TNF)-α antagonists for the treatment of rheumatoid arthritis (RA). The study is…
Abstract Number: 1829 • 2012 ACR/ARHP Annual Meeting
Cost of Etanercept, Adalimumab, and Infliximab in Patients with Rheumatoid Arthritis with Employer Provided Health Insurance
Machaon Bonafede¹, Crystal Watson², George Joseph², Nicole Princic¹ and David J. Harrison², ¹Thomson Reuters Healthcare, Cambridge, MA, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Tumor Necrosis Factor Inhibitors (TNFi) are the mainstay of treatment for rheumatoid arthritis (RA) in patients with moderate to severe disease. The three most…
Abstract Number: 486 • 2012 ACR/ARHP Annual Meeting
Impact of Adalimumab Therapy On Laboratory Parameters of Interest in Patients with Early or Long-Standing Rheumatoid Arthritis
Daniel Furst¹, Ana P. Lacerda², Nupun Andhivarothai³, Jasmina Kalabic⁴ and Neelufar Mozaffarian³, ¹David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ²Abbott Laboratories, São Paulo, Brazil, ³Abbott Laboratories, Abbott Park, IL, ⁴Abbott GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: The systemic inflammation of rheumatoid arthritis (RA) can have detrimental effects on the hematopoietic and cardiovascular systems. Additionally, effective DMARD treatments for RA can…
Abstract Number: 1641 • 2012 ACR/ARHP Annual Meeting
When Can Biological Therapy Be Resumed in Patients with Rheumatic Conditions Who Develop Tuberculosis Infection During Tumour Necrosis Factors Antagonists Therapy? Study Based On the Biobadaser Data Registry
Maria Victoria Hernández¹, Miguel A. Descalzo², Juan D. Cañete¹, Raimon Sanmarti³ and BIOBADASER Study Group⁴, ¹Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Research Unit. Spanish Society of Rheumatology, Madrid, Spain
Background/Purpose: Tuberculosis infection (TI) is one of the most serious adverse events related to tumour necrosis factor (TNF) antagonists. According to the current treatment guidelines…
Abstract Number: 487 • 2012 ACR/ARHP Annual Meeting
Functional Disability in Early Rheumatoid Arthritis – Contributions of Disease Activity and Structural Damage, and the Impact of Different Treatment Strategies
Josef S. Smolen¹, Roy Fleischmann², Paul Emery³, Ronald F. van Vollenhoven⁴, Stefan Florentinus⁵, Freddy Faccin⁶, Suchitrita S. Rathmann⁷, Hartmut Kupper⁸ and Arthur Kavanaugh⁹, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ³Medicine, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴Unit for Clinical Trial Therapy research, The Karolinska Institute, Stockholm, Sweden, ⁵AbbVie, Rungis, France, ⁶Abbott, Abbott Park, IL, ⁷Abbott Laboratories, Abbott Park, IL, ⁸Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, ⁹UCSD School of Medicine, La Jolla, CA
Background/Purpose: Functional impairment among patients with rheumatoid arthritis (RA) can be conceptualized as consisting of a reversible component that relates to disease activity (ACT-HAQ) and…
Abstract Number: 1383 • 2012 ACR/ARHP Annual Meeting
The Burden of Ankylosing Spondylitis and the Cost-Effectiveness of Anti-Tumor Necrosis Factor α Agents in Romania
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴ and Mihai Bojinca¹, ¹Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania
Background/Purpose: Ankylosing Spondylitis (AS) usually affects young males, severely impairing their quality of life. Chronic treatment of AS using anti-TNF α agents is costly and…
Abstract Number: 373 • 2012 ACR/ARHP Annual Meeting
Patient-Reported Outcomes in Early Rheumatoid Arthritis Patients Failing to Achieve Stable Low Disease Activity: Comparing Addition of Adalimumab to Methotrexate Monotherapy with Maintenance On Adalimumab Plus Methotrexate
Arthur Kavanaugh¹, Ronald F. van Vollenhoven², Paul Emery³, James W. Shaw⁴, Mary A. Cifaldi⁵, Stefan Florentinus⁶ and Josef S. Smolen⁷, ¹UCSD School of Medicine, La Jolla, CA, ²Karolinska Institute, Stockholm, Sweden, ³Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁴Global Health Economics and Outcomes Research, Abbott Laboratories, Abbott Park, IL, ⁵Abbott Laboratories, Abbott Park, IL, ⁶AbbVie, Rungis, France, ⁷Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Treat-to-target guidelines for rheumatoid arthritis (RA) suggest adjusting therapy every 3-6 months for pts who fail to achieve a disease activity target. However, pts…
Abstract Number: 1340 • 2012 ACR/ARHP Annual Meeting
Effects of Subcutaneous Abatacept or Adalimumab On Remission and Associated Changes in Physical Function and Radiographic Outcomes: One Year Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Trial
Roy Fleischmann¹, Michael H. Schiff², Michael E. Weinblatt³, Michael A. Maldonado⁴, Elena M. Massarotti⁵ and Yusuf Yazici⁶, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Rheumatology Division, University of Colorado, Denver, CO, ³Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ⁴Medical Strategy, Bristol-Myers Squibb, Princeton, NJ, ⁵Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶New York University, New York, NY
Background/Purpose: Advancements in the understanding of Rheumatoid Arthritis (RA) have led to the development of novel therapeutics and treatment guidelines that target remission as an…
Abstract Number: 386 • 2012 ACR/ARHP Annual Meeting
Costs of Tumor Necrosis Factor Blockers Per Treated Rheumatoid Arthritis Patient Using Real-World Drug Data in a US Managed Care Population
Vernon F. Schabert¹, Crystal Watson², George Joseph², Paige Iversen¹, Chakkarin Burudpakdee¹ and David J. Harrison², ¹IMS Health, Alexandria, VA, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Etanercept (ETN), adalimumab (ADA), and infliximab (INF) are FDA-approved tumor necrosis factor (TNF)-blocker treatments for moderate to severe rheumatoid arthritis (RA) and are commonly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].